Potential breakthrough therapeutic for estimated $50+ billion global immunotherapy market; first and only telomere-targeting anticancer agent in clinical development anywhere CHICAGO, Jan. 20, 2026 ...
“Designing treatments unique to individual patients has always been the promised goal of personalized medicine. After 25 years the FDA has, for the first time, outlined a framework to facilitate these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results